1.1. Рациональная фармакотерапия в акушерстве и гинекологии. Руководство для практических врачей. Под ред. В.И.Кулакова, В.Н.Серова. М.: Литтерра, 2005; с. 724-7.2.2. Справочник по акушерству, гинекологии и перинатологии. Под ред. Г.М.Савельевой. М.: МИА, 2006; с. 487-501.3.3. Banikarim C, Chacko MR. Pelvic inflammatory disease in adolescents. Semin Pediatr Infect Dis 2005; 16 (3): 175-80.4.4. Серов В.Н, Тихомиров А.Л. Современные принципы терапии воспалительных заболеваний женских половых органов. Методическое пособие. М., 2002.5.5. Beigi RH, Wiesenfeld HC. Pelvic inflammatory disease: new diagnostic criteria and treatment. Obstet Gynecol Clin North Am 2003; 30 (4): 777-93.6.6. Тихомиров А.Л., Сарсания С.И. Воспалительные заболевания женских половых органов. Брошюра практического гинеколога, 2007.7.7. Тихомиров А.Л. Значение адекватной антибактериальной терапии воспалительных заболеваний органов малого таза для сохранения репродуктивного женского здоровья. Трудный пациент. 2010; 8 (1-2): 9-12.8.8. Ершов Г.В., Бочкарев Д.Н., Смоленов И.В. Этиологическая структура и резистентность возбудителей воспалительных заболеваний органов малого таза у женщин. Клин. микробиология и антимикроб. химиотерапия. 2004; 6 (2): 193-200.9.9. Boeke AJ. The risk of pelvic inflammatory disease with urogenital infection with Chlamydia trachomatis. Ned Tijdschr Geneeskd 2005; 16 (149): 878-84.10.10. CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: RR-12.11.11. Cohen CR, Manhart LE, Bukusi EA et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765-6.12.12. RCOG Green Top Guidelines-Management of Pelvic Inflammatory Disease (2003, 2009). www.rcog.org.uk13.13. Clarke LM, Duerr А, Yeung КН. Recovery of cytomegalovirus and herpes simplex virus from upper and lower genital tract specimens obtained from women with pelvic inflammatory disease. J Infect Dis 1997; 1 (176): 286-8.14.14. Ross JD. Is Mycoplasma genitalium a cause of pelvic inflammatory disease? Infect Dis Clin North Am 2005; 19 (2): 407-13.15.15. Performance Standards for Antimicrobial Susceptibility Testing. National Committee for Clinical and Laboratory Standards (NCCLS) 2001; 21 (1): 123.16.16. Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. М., 2007; с. 294-5.17.17. Страчунский Л.С., Кречиков В.А. Моксифлоксацин - фторхинолон нового поколения с широким спектром активности. Клин. микробиология и антимикроб. химиотерапия. 2001; 3 (3): 243-59.18.18. Страчунский Л.С., Веселов А.В., Кречиков В.А. Моксифлоксацин: настоящее и будущее в ступенчатой терапии. Клин. микробиология и антимикроб. химиотерапия. 2003; 5 (1): 19-31.19.19. MacGowan A, Bowker K, Holt H, Wootton M et al. BAY 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother 1997; 40: 503-9.20.20. Wise R, Andrews J, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999; 43: 1508-10.21.21. Lettieri J, Vargas R, Agarwal V, Liu P. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers. Clin Pharmacokinet 2001; 40 (Suppl. 1): 19-25.22.22. Ballow C, Lettieri J, Agarwal V, Liu P et al. Absolute bioavailability of moxifloxacin. Clin Ther 1999; 21: 513-22.23.23. Lubasch A, Keller I, Borner K, Koeppe P et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-3.24.24. Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40 (Suppl. 1): 33-8.25.25. Sullivan J, Lettieri J, Liu P, Heller A. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet 2001; 40 (Suppl. 1): 11-8.26.26. Stass H, Halabi A, Delesen H. No dose adjustment needed for patients with renal impairment receiving oral BAY 12-8039 (M). Proceedings of the 38th ICAAC, 1998; San Diego, USA; p. 5.27.27. Stass H, Kubitza D. No dose adjustment is needed for moxifloxacin (MOX) in subjects suffering from hepatic impairment (HI). Clin Microb Infection 1999; 5 (Suppl. 3): 291.28.28. Zhanel G, Walters M, Karlowsky J, Laing N et al. Activity of free (unbound) fluoroquinolone serum concentrations versus multi-drug resistant Streptococcus pneumoniae using an in vitro pharmacodynamic model. Proceedings of the 40th ICAAC, 2000; Toronto, Canada; p. 7.29.29. Wright D, Brown G, Peterson M, Rotschafer J. Application of fluoroquinolones pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-83.30.30. Boswell F, Andrews J, Wise R, Dalhoff A. Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999; 43 (Suppl. B): 43-9.31.31. Ricci V, Piddock L. Characterization of the QRDR of gyrA of Bacteroides fragilis and role in fluoroquinolone resistance. Proceedings of the 38th ICAAC, 1998; San Diego, USA; p. 121.32.32. Nord C, Edlund C. Susceptibility of anaerobic bacteria to BAY 12-8039, a new methoxyquinolone. Clin Microb Infection 1997; 3 (Suppl. 2): 285.33.33. Kubin R, Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. Proceedings of the 40th ICAAC, 2000; Toronto, Canada; p. 477.34.34. Kretchikov VA, Dekhnich AV, Startchounski LS. Comparative activity of old and new quinolones against nosocomial Staphylococcus aureus. Proceeding of 12th ECCMID, 2002; Milan, Italy. Abstract P1145.35.35. Bebear CM, Renaudin H, Boudjadja A, Bebear C. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother 1998; 42: 703-4.36.36. Takahata M, Shimakura M, Hori R et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 2001; 45: 312-5.37.37. Ullmann U, Schubert S, Krausse R. Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother 1999; 43 (Suppl. C): 33-6.38.38. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 (Suppl. B): 83-90.39.39. Kubin R, Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. Proceedings of the 40th ICAAC, 2000; Toronto, Canada; p. 477.40.40. Springsklee M, Reiter C, Meyer J. Safety and Tolerability Profile of Moxifloxacin (MXF). Clin Microb Infection 1999; 5 (Suppl. 3): 140.41.41. Fogarty C, Grossman C, Williams J, Haverstock D et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748-63.42.42. Hoffken G, Meyer H, Sprenger K, Verhoef L. Efficacy and safety of moxifloxacin (MXF) vs clarithromycin (Кларитро) for the treatment of community-acquired pneumonia (CAP). J Antimicrob Chemother 1999; 44 (Suppl. A): 127.43.43. Chodosh S, DeAvate C, Haverstock D, Aneiro L et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Resp Med 2000; 94: 18-27.44.44. Wilson R, Kubin R, Ballin I et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-13.45.45. Burke T, Villanueva C, Mariano H et al. Comparison of Moxifloxacin and Cefuroxime Axetil in the treatment of acute maxillary sinusitis. Clinical therapeutics, 1999; vol. 21; 10: 1664-7746.46. Vohr H, Wasinka-Kempka G, Ahr H. Studies on the Phototoxic Potential of a new 8-Methoxy-quinolone: BAY 12-8039. Proceedings of the 36th ICAAC, 1996; New Orleans, USA; p. 103.47.47. Man I, Murphy J, Fergeson J. Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. J Antimicrob Chemother 1999; 43 (Suppl. B): 77-82.48.48. Siepmann M, Kirch W. Tachycardia associated with moxifloxacin. BMJ 2001; 322: 23.49.49. Ferguson J, Alajmi H, Kubin R, Dagget S et al. A double-blind, placebo- and lomefloxacin-controlled human volunteer phototest study to determine the photosensitising potential of oral moxifloxacin (BAY 12-8039). Proceedings of the 8th ICID9, 1998; Boston, USA; p. 197.50.50. Kubitza D, Delesen H. Influence of oral moxifloxacin on the QTs interval of healthy volunteers. Proceedings of the 40th ICAAC, 2000; Toronto, Canada; p. 475.51.51. Hollister A, Haverstock D, Choudhri S. Moxifloxacin has a favorable cardiovascular safety profile in patients taking concominant QTs prolonging drugs. Proceedings of the 40th ICAAC8; 2000 Sep 17-20; Toronto, Canada. p. 476.52.52. Beyer G, Hiemer-Bau M, Ziege S, Edlund C et al. Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. Eur J Clin Microbiol Infect Dis 2000; 19: 548-50.53.53. Edlund C, Beyer G, Hiemer-Bau M, Ziege S et al. Comparative effects of moxifloxacin and clarithromycin on normal intestinal microflora. Scan J Infect Dis 2000; 32: 81-5.54.54. Heystek M, Tellarini M, Schmitz H, Krasemann C. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemother 1999; 44 (Suppl. A): 143.55.55. Ross JDC, Cronje HS, Paskowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double-blind, randomized trial. Sex Transm Infect 2006; 82: 446-51.